How FIRAZYR works
FIRAZYR is used to treat acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. FIRAZYR is the first and only FDA-approved injection you give yourself under the skin (subcutaneously) to treat acute attacks of HAE—both in and out of the home—after you have been trained by a healthcare professional.
How does FIRAZYR work?
Most people with HAE don’t have enough of a protein called C1 esterase inhibitor, or this protein does not work as it should, which contributes to a cascade of events in the body. This cascade causes another protein called plasma kallikrein to trigger the release of a third protein called bradykinin. Having too much bradykinin causes the blood vessels to release fluid, resulting in localized swelling.
FIRAZYR works by blocking bradykinin from binding to B2 receptors, which reduces the activity of bradykinin and thereby treats the symptoms of acute attacks of HAE.
Treat with FIRAZYR as soon as symptoms are recognized
FIRAZYR can be used to treat all types of acute HAE attacks, including skin (cutaneous), stomach (abdominal), and throat (laryngeal).
In the pivotal trial (Trial 1), the median time to 50% reduction in symptoms was 2.0 hours for those treated with FIRAZYR vs 19.8 hours for those given placebo
In Trial 1, the median time to almost complete symptom relief was 8.0 hours vs 36.0 hours for FIRAZYR and placebo, respectively
Across 3 controlled clinical trials, median time to 50% reduction from baseline symptoms ranged from 2.0 to 2.3 hours with FIRAZYR
In clinical trials, 9 of 10 attacks were treated with a single dose of FIRAZYR
In controlled studies:
- FIRAZYR was used to treat acute HAE attacks of the throat in 60 patients. Symptom reduction was similar to results seen for skin and abdominal attacks. It is important to know that laryngeal (throat) attacks can become life-threatening. If you have an HAE attack involving the throat, inject FIRAZYR as directed and then go to the nearest hospital emergency room right away.
Response to FIRAZYR for multiple attacks of acute HAE
Across controlled trials (FAST-1, -2 & -3), an analysis showed that the median time to 50% symptom reduction with FIRAZYR was consistent for up to 5 separate non-throat attacks.